![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Merck known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer’s Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.
At the conference, Merck scientists are scheduled to present results from multiple preclinical and clinical studies investigating the safety and efficacy of ß-amyloid precursor protein site cleaving enzyme (BACE) inhibitors, including MK-8931, the company’s lead compound currently being investigated as a potential treatment for Alzheimer’s disease.
“The prevalence of Alzheimer’s disease is growing rapidly due to the aging population, creating an unsustainable burden on patients, caregivers and the economy,” said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories. “Merck is committed to discovering and developing novel medicines to treat neurodegenerative brain diseases, such as Alzheimer’s and dementia, and is focused on rapidly advancing its BACE inhibitor program.”
Select Merck presentations at AAIC include:
July 15, 2012
P1-221: Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single and multiple dose administration.
P1-225: A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK-8931 in Japanese subjects.
P1-229:Population pharmacokinetic modeling of the novel BACE inhibitor MK-8931 following single and multiple dose administration in healthy subjects.
July 18, 2012
P4-196: The novel BACE inhibitor MK-8931 dramatically lowers CSF Abeta peptides in healthy subjects following single and multiple dose administration.
Earlier this year, Merck disclosed the results of a two part randomized, double-blind, placebo-controlled single dose study evaluating the safety and tolerability of MK-8931 in 40 healthy adults 18 to 45 years of age. Single doses of MK-8931 were associated with marked reductions in amyloid beta peptide concentration levels with a mean reduction from baseline of up to 92 percent. MK-8931 was generally well tolerated in these healthy subjects with no serious adverse events and no study discontinuations. Adverse events were generally mild to moderate in intensity and transient in duration and included headache (57 percent and 50 percent), nasal congestion (23 percent and 30 percent) and dizziness (20 percent and 40 percent, for MK-8931 and placebo respectively).
About BACE
The amyloid hypothesis predicts that abnormal accumulation of amyloid-ß peptide is a central event in the progression of Alzheimer’s disease. The enzyme BACE is a key enzyme in the initiation of synthesis of amyloid ß peptide. Inhibition of BACE is therefore believed to provide a promising means for therapeutic intervention in Alzheimer’s disease.
About Merck
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
